Award

National Heart, Lung, and Blood Institute 5F30HL172628-02

Therapeutic potential of CC-90009 for cystic fibrosis

Recipient

University of North Carolina at Chapel Hill

Award Amount

$41,184.00

Ceiling

$41,184.00

Awarded

August 27, 2025

Identifier

5F30HL172628-02

This award supports research on CC-90009 as a potential therapy for cystic fibrosis, focusing on its effects on CFTR function and ENaC activity to improve lung function in patients with specific genetic variants.

Description

The project investigates the therapeutic potential of CC-90009, a thalidomide derivative, which promotes ribosomal readthrough to rescue PTC-CFTR variants and reduces ENaC activity, aiming to improve mucociliary transport in CF and other lung diseases.

View original record